Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

T. Peter Kingham

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3359-3186; OpenAlex author ID A5070901426. Sources: OpenAlex.

Their work

Papers
28 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
90
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 4 papers · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 4 papers · 2023: 2 papers · 2024: 2 papers · 2025: 4 papers

Papers 28

  1. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  2. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  3. Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer. Co-author DOI 10.1200/op-24-00528↗
  4. Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection. Co-author DOI 10.1245/s10434-025-17199-8↗
  5. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  6. Treatment Patterns and Outcomes in Pancreatic Cancer: A Comparative Analysis of Ontario and the USA. Co-author DOI 10.1245/s10434-023-14375-6↗
  7. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  8. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-3089↗
  9. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26735↗
  10. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  11. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adeno… Co-author DOI 10.1177/0003134821989050↗
  12. Recurrence After Resection of Pancreatic Cancer: Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis? Co-author DOI 10.1245/s10434-022-11579-0↗
  13. Treatment patterns and survival in patients with early-onset pancreatic cancer. Co-author DOI 10.1002/cncr.33664↗
  14. Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. Co-author DOI 10.1007/s00261-020-02726-w↗
  15. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Co-author DOI 10.1097/sla.0000000000005080↗
  16. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  17. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-019-02112-1↗
  18. Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Co-author DOI 10.1007/s00261-017-1407-x↗
  19. The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.09.001↗
  20. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancrea… Co-author DOI 10.1016/j.hpb.2017.12.010↗
  21. Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. Co-author DOI 10.1245/s10434-017-6323-3↗
  22. Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer. Last author DOI 10.1245/s10434-016-5757-3↗
  23. Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.24125↗
  24. A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.1007/s11605-015-3057-z↗
  25. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-015-4647-4↗
  26. Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? Co-author DOI 10.1007/s11605-012-2071-7↗
  27. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-match… Co-author DOI 10.1111/hpb.12033↗
  28. Operative procedures for unresectable pancreatic cancer: does operative bypass decrease requirements for postoperative procedures and in-hospital days? Co-author DOI 10.1111/j.1477-2574.2012.00477.x↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William R. Jarnagin · 26 shared papers, 2012–2025 · strength 2.73
  2. Michael Ian D'Angelica · 25 shared papers, 2012–2025 · strength 2.67
  3. Jeffrey A. Drebin · 14 shared papers, 2019–2025 · strength 1.92
  4. Vinod P. Balachandran · 15 shared papers, 2018–2025 · strength 1.82
  5. Alice Chia-Chi Wei · 11 shared papers, 2021–2025 · strength 1.71
  6. Kevin C. Soares · 10 shared papers, 2021–2025 · strength 1.58
  7. Eileen Mary O'Reilly · 10 shared papers, 2015–2025 · strength 1.27
  8. Anna M. Varghese · 8 shared papers, 2020–2025 · strength 1.12
  9. Peter J. Allen · 15 shared papers, 2012–2022 · strength 1.04
  10. Christopher H. Crane · 4 shared papers, 2021–2025 · strength 0.65
  11. Caitlin A. McIntyre · 6 shared papers, 2019–2022 · strength 0.65
  12. Wungki Park · 4 shared papers, 2020–2025 · strength 0.51
  13. Richard Kinh Gian Do · 6 shared papers, 2015–2022 · strength 0.50
  14. Kenneth H. Yu · 4 shared papers, 2020–2025 · strength 0.49
  15. Amber L. Simpson · 5 shared papers, 2018–2022 · strength 0.45
  16. Marinela Capanu · 3 shared papers, 2020–2025 · strength 0.36
  17. Marsha Reyngold · 2 shared papers, 2021–2025 · strength 0.34
  18. Joshua S. Jolissaint · 2 shared papers, 2021–2025 · strength 0.34
  19. Lily V. Saadat · 2 shared papers, 2021–2024 · strength 0.31
  20. Christine A. Iacobuzio–Donahue · 3 shared papers, 2019–2023 · strength 0.31
  21. Olca Baştürk · 3 shared papers, 2018–2025 · strength 0.29
  22. Quisette P. Janssen · 2 shared papers, 2022–2023 · strength 0.28
  23. Jayasree Chakraborty · 3 shared papers, 2018–2022 · strength 0.27
  24. David Paul Kelsen · 2 shared papers, 2020–2025 · strength 0.26
  25. Linda M. Pak · 3 shared papers, 2017–2018 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.